Multidisciplinary care for patients with Multiple System Atrophy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the disease burden of Multiple System Atrophy (MSA) and evaluate the effects of multidisciplinary care on patients' quality of life and caregiver burden. Participants will attend a specialized MSA clinic every four months and complete various validated questionnaires to gather data on their condition and care experience. The study will follow participants for up to five years to monitor changes and outcomes related to their care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject must be a patient in the UT Southwestern MSA clinic and be able to attend the multidisciplinary clinic every 4 months
* Patients with possible or probable MSA based on established criteria
* Subjects must be 18 years or older

Exclusion Criteria:

* Patients that are unable to give consent
* Minor patients (younger than age 18)
* Non-English speaking patients
* Subjects that are diagnosed with dementia

Where it's running

• UT Southwestern Medical Center
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Steven Vernino, M.D. — University of Texas Southwestern Medical Center
• Study coordinator: Amy Conger
• Email: Amy.Conger@UTSouthwestern.edu
• Phone: 214-648-0214

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging with MODAG-009 PET to See Synuclein in PD, MSA, and Healthy Adults

  This study tests a new PET tracer, MODAG-009, in people with Parkinson's, Multiple System Atrophy, and healthy adults to see how well it images synuclein in the brain.

  Recruiting Early Phase 1 MODAG GmbH · New Haven, Connecticut · NCT07640555

• SST001 PET tracer safety and pharmacokinetics in healthy adults and people with PD or MSA

  This study tests SST001, a PET tracer, to see if it is safe and how it behaves in the body for healthy adults and people with Parkinson’s disease or multiple system atrophy.

  Recruiting at 2 sites Phase 1 Synusight Biotech (Shanghai) Co., Ltd. · Wuxi, Jiangsu and 1 other locations · NCT07604116

• MSA-01 to try to slow progression of Multiple System Atrophy

  This trial will test whether MSA-01 (a bioavailable form of CoQ10) can slow motor worsening in people with probable or established MSA over 52 weeks.

  Recruiting Phase 3 Tokyo University · Nagoya, Aichi-ken and 11 other locations · NCT07446894

• Using AI to improve the levodopa challenge test for Parkinson's disease diagnosis

  This study is testing a new way to diagnose Parkinson's disease using artificial intelligence and video recordings to see if it can improve the accuracy of the levodopa challenge test.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT06949865

• Testing a new PET tracer for measuring brain protein in neurodegenerative diseases

  This study is testing a new imaging tool to see if it can help detect a specific brain protein in people with conditions like Parkinson's Disease and Dementia.

  Recruiting Early Phase 1 AC Immune SA · Solna · NCT06891703

• Aleeto for Parkinsonian multiple system atrophy (MSA-P)

  This study will test whether Aleeto is safe and might help people with the Parkinsonian form of multiple system atrophy.

  Recruiting Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality · NCT06765733

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.